Abstracts
The importance of the kidney in glucose homeostasis has been recognized for many years. Recent observations indicating a greater role of renal glucose metabolism in various physiologic and pathologic conditions have rekindled the interest in renal glucose handling as a potential target for the treatment of diabetes. The enormous capacity of the proximal tubular cells to reabsorb the filtered glucose load entirely, utilizing the sodium-glucose co-transporter system (primarily SGLT-2), became the focus of attention. Original studies conducted in experimental animals with the nonspecific SGLT inhibitor phlorizin showed that hyperglycemia after pancreatectomy decreased as a result of forced glycosuria. Subsequently, several compounds with more selective SGLT-2 inhibition properties (“second-generation”) were developed. Some agents made it into pre-clinical and clinical trials and a few have already been approved for commercial use in the treatment of type 2 diabetes. In general, a 6-month period of therapy with SGLT-2 inhibitors is followed by a mean urinary glucose excretion rate of ~80 g/day accompanied by a decline in fasting and postprandial glucose with average decreases in HgA1C ~1.0%. Concomitant body weight loss and a mild but consistent drop in blood pressure also have been reported. In contrast, transient polyuria, thirst with dehydration and occasional hypotension have been described early in the treatment. In addition, a significant increase in the occurrence of uro-genital infections, particularly in women has been documented with the use of SGLT-2 inhibitors.
Conclusion:
Although long-term cardiovascular, renal and bone/mineral effects are unknown SGLT-2 inhibitors, if used with caution and in the proper patient provide a unique insulin-independent therapeutic option in the management of obese type 2 diabetes patients.
diabetes mellitus, type 2/therapy; glycosuria; kidney, sodium-glucose transporter 2
A importância do rim na homeostase de glicose é reconhecida desde há muitos anos. Observações recentes, indicando um papel maior do metabolismo renal da glicose em várias condições fisiológicas e patológicas, reavivaram o interesse no manuseio renal de glicose como um alvo em potencial para o tratamento do diabetes. A enorme capacidade das células tubulares proximais para reabsorver a carga total de glicose filtrada, utilizando o sistema de co-transporte de sódio e glicose (SGLT), tornou-se o foco de atenção. Estudos originais realizados em animais experimentais com o uso do inibidor não-específico da SGLT florizina, demonstraram que a hiperglicemia após pancreatectomia diminuiu como resultado de glicosúria forçada. Posteriormente, foram desenvolvidas diversas substâncias com propriedades mais seletivas de inibição da SGLT-2 ("segunda geração"). Vários agentes foram usados em ensaios pré-clínicos e clínicos, e alguns já foram aprovados para uso comercial no tratamento da diabetes tipo 2. Em geral, os dados clinicos mostram que um período de 6 meses de tratamento com inibidores da SGLT-2 é seguido por uma taxa de excreção de glicose urinária média de ~ 80 g/dia, acompanhado por uma queda na glicemia de jejum e pós-prandial e com redução média na HbA1C de - 1.0%. Também foram relatados perda concomitante no peso corpóreo e uma leve mas consistente queda da pressão arterial. Em contraste, eventos adversos transitórios como poliúria, sede com desidratação e hipotensão ocasional foram descritos na fase inicial de tratamento. Além disso, um aumento significativo na ocorrência de infecções urogenitais, particularmente em mulheres, foi documentado com o uso de inibidores da SGLT-2. Os efeitos cardiovasculares, renais e ósseo/minerais a longo prazo destes agentes ainda são desconhecidos.
Conclusão:
Os inibidores da SGLT-2, se usados de forma criteriosa e em pacientes adequados, representam uma opção terapêutica única, que explora um novo mecanismo de ação anti-hiperglicêmico independente da insulina. Estão portanto indicados, tanto na monoterapia ou em combinação com outros agentes no tratamento de pacientes obesos com diabetes tipo 2.
diabetes mellitus tipo 2/terapia; glicosúria; rim; transportador 2 de glucose-sódio
Introduction
The importance of the kidney in glucose homeostasis has been recognized for many
years.11. Krebs HA, Hems RA, Gascoyne T. Renal gluconeogenesis. IV.
Gluconeogenesis from substrate combinations. Acta Biol Med Ger
1963;11:607-15.,22. Cahill GF Jr. Starvation in man. N Engl J Med 1970;282:668-75. DOI:
http://dx.doi.org/10.1056/NEJM197003192821209
http://dx.doi.org/10.1056/NEJM1970031928...
A critical observation indicating that the renal contribution to
glucose regulation and counter-regulation might perhaps be of greater significance than
previously anticipated was reported in the early 1990's.33. Cersosimo E, Judd RL, Miles JM. Insulin regulation of renal glucose
metabolism in conscious dogs. J Clin Invest 1994;93:2584-9. DOI:
http://dx.doi.org/10.1172/JCI117270
http://dx.doi.org/10.1172/JCI117270...
This publication rekindled the interest in the role of the kidney in
glucose metabolism and several studies in animals44. Cersosimo E, Ajmal M, Naukam RJ, Molina PE, Abumrad NN. Role of the
kidney in plasma glucose regulation during hyperglycemia. Am J Physiol
1997;272:E756-61. PMID: 9176172
5. Cersosimo E, Molina PE, Abumrad NN. Renal lactate metabolism and
gluconeogenesis during insulin-induced hypoglycemia. Diabetes 1998;47:1101-6. DOI:
http://dx.doi.org/10.2337/diabetes.47.7.1101
http://dx.doi.org/10.2337/diabetes.47.7....
-66. Eid A, Bodin S, Ferrier B, Delage H, Boghossian M, Martin M, et al.
Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic
fatty rats. J Am Soc Nephrol 2006;17:398-405. DOI:
http://dx.doi.org/10.1681/ASN.2005070742
http://dx.doi.org/10.1681/ASN.2005070742...
and humans77. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich
J. Uptake and release of glucose by the human kidney. Postabsorptive rates and
responses to epinephrine. J Clin Invest 1995;96:2528-33. DOI:
http://dx.doi.org/10.1172/JCI118314
http://dx.doi.org/10.1172/JCI118314...
8. Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal
glucose metabolism in humans. Am J Physiol 1999;276:E78-84. PMID: 9886953 DOI:
http://dx.doi.org/10.2337/diabetes.48.2.261
http://dx.doi.org/10.2337/diabetes.48.2....
9. Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S,
Brunengraber H, et al. Contributions by kidney and liver to glucose production in the
postabsorptive state and after 60 h of fasting. Diabetes 1999;48:292-8. DOI:
http://dx.doi.org/10.2337/diabetes.48.2.292
http://dx.doi.org/10.2337/diabetes.48.2....
-1010. Cersosimo E, Garlick P, Ferretti J. Abnormal glucose handling by the
kidney in response to hypoglycemia in type 1 diabetes. Diabetes 2001;50:2087-93. DOI:
http://dx.doi.org/10.2337/diabetes.50.9.2087
http://dx.doi.org/10.2337/diabetes.50.9....
subsequently demonstrated the potential impact of renal glucose handling
in various physiologic and pathologic conditions. Concomitantly, the pharmacological
development of new agents capable of inhibiting renal glucose reabsorption was
accelerated and has now reached clinical relevance. As a result, the kidney has become
an additional target for anti-diabetic medications.
Renal glucose handling includes free glomerular filtration with complete proximal tubular reabsorption into the renal interstitial fluid space. Renal gluconeogenesis that takes place in the proximal tubular cells adds a small fraction to the glucose load that exchanges with the peri-tubular capillaries along the proximal nephron. In the distal nephron, glucose extracted can be either stored in the form of glycogen or oxidized to generate energy. In turn, no glucose is excreted in the urine and nearly all filtered glucose load perfusing the distal nephron is restored to the peripheral circulation, after mixing in the renal vein with the remainder 80% of unfiltered blood.1111. Wirthensohn G, Guder WG. Renal substrate metabolism. Physiol Rev 1986;66:469-97. PMID: 2938198
The evidence for the heterogeneity of glucose handling within the nephron (Figure 1) is substantiated by numerous reports in the
literature.11. Krebs HA, Hems RA, Gascoyne T. Renal gluconeogenesis. IV.
Gluconeogenesis from substrate combinations. Acta Biol Med Ger
1963;11:607-15.,1212. Weidemann MJ, Krebs HA. The fuel of respiration of rat kidney
cortex. Biochem J 1969;112:149-66. PMID: 5805283
13. Klein KL, Wang MS, Torikai S, Davidson WD, Kurokawa K. Substrate
oxidation by isolated single nephron segments of the rat. Kidney Int 1981;20:29-35.
PMID: 7300110 DOI: http://dx.doi.org/10.1038/ki.1981.100
http://dx.doi.org/10.1038/ki.1981.100...
14. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int
1984;26:101-11. DOI: http://dx.doi.org/10.1038/ki.1984.143
http://dx.doi.org/10.1038/ki.1984.143...
-1515. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal
Physiol 2001;280:F10-8. PMID: 11133510 Several
studies have defined the molecular structure and the enormous enzymatic and transport
capacity of the renal tubules. The sodium-glucose co-transport system (SGLT) is located
at the luminal membrane of the proximal renal tubular cells.1515. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal
Physiol 2001;280:F10-8. PMID: 11133510 These cells contain specific enzymes that enable glucose
synthesis de novo [renal gluconeogenesis],11. Krebs HA, Hems RA, Gascoyne T. Renal gluconeogenesis. IV.
Gluconeogenesis from substrate combinations. Acta Biol Med Ger
1963;11:607-15.,1212. Weidemann MJ, Krebs HA. The fuel of respiration of rat kidney
cortex. Biochem J 1969;112:149-66. PMID: 5805283 although no
enzymatic activity for concomitant glucose utilization, storage or oxidation has ever
been identified in proximal tubules.1414. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int
1984;26:101-11. DOI: http://dx.doi.org/10.1038/ki.1984.143
http://dx.doi.org/10.1038/ki.1984.143...
Schematic representation of the nephron showing the heterogeneity of glucose handling by the kidney. Plasma glucose is freely filtered at the glomerulus and completely reabsorbed in the proximal tubules. The SGLT-2 transporters located at the luminal membrane of cells in the S1 and S2 segments are responsible for 90% of total glucose re-uptake. The SGLT-1 transporters located downstream in the S3 segment of the proximal tubules account for the remainder 10% of the glucose load reabsorbed into the renal interstitial fluid. The process of renal gluconeogenesis occurs exclusively in the proximal tubular cells, whereas glucose utilization is limited to the distal nephron. Glycogen synthesis and storage, as well as complete glucose oxidation are detected only in cells of the distal nephron and, partial oxidation (anaerobic glycolysis) with formation and release of lactate is a characteristic of the hypoxic medullary regions of the kidney.
In contrast, the distal nephron has sufficient biochemical capability to metabolize the
glucose extracted from the peri-tubular fluid and, the renal medulla is in fact an
obligatory site for glucose oxidation.1313. Klein KL, Wang MS, Torikai S, Davidson WD, Kurokawa K. Substrate
oxidation by isolated single nephron segments of the rat. Kidney Int 1981;20:29-35.
PMID: 7300110 DOI: http://dx.doi.org/10.1038/ki.1981.100
http://dx.doi.org/10.1038/ki.1981.100...
,1414. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int
1984;26:101-11. DOI: http://dx.doi.org/10.1038/ki.1984.143
http://dx.doi.org/10.1038/ki.1984.143...
Because most of the
energy required by the mega-transport tubular activity is supplied primarily from the
oxidation of fatty acids, glucose sparing by the kidney is enabled and represents a
critical aspect in the maintenance of whole-body glucose homeostasis.
Renal glucose transport and metabolism
Various glucose transmembrane transport systems and intracellular metabolic pathways
have been well characterized in the kidney. Most information is derived from
in vitro cell preparations1616. Aronson PS, Sacktor B. The Na+ gradient-dependent transport of
D-glucose in renal brush border membranes. J Biol Chem 1975;250:6032-9. PMID:
1150669
17. Turner RJ, Moran A. Heterogeneity of sodium-dependent D-glucose
transport sites along the proximal tubule: evidence from vesicle studies. Am J
Physiol 1982;242:F406-14. PMID: 6278960-1818. Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and
cDNA sequencing of the Na+/glucose co-transporter. Nature 1987;330:379-81. PMID:
2446136 DOI: http://dx.doi.org/10.1038/330379a0
http://dx.doi.org/10.1038/330379a0...
and renal
perfusion studies using experimental animal models.1919. Sacktor B. Sodium-coupled hexose transport. Kidney Int
1989;36:342-50. PMID: 2687560 DOI:
http://dx.doi.org/10.1038/ki.1989.202
http://dx.doi.org/10.1038/ki.1989.202...
20. Lee WS, Kanai Y, Wells RG, Hediger MA. The high affinity Na+/glucose
cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem
1994;269:12032-9. PMID: 8163506-2121. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose
cotransporters. Physiol Rev 1994;74:993-1026. Analogous findings
have been reported in a few studies conducted in human kidney.2222. Mogensen CE. Maximum tubular reabsorption capacity for glucose and
renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic
subjects. Scand J Clin Lab Invest 1971;28:101-9. PMID: 5093515 DOI:
http://dx.doi.org/10.3109/00365517109090668
http://dx.doi.org/10.3109/00365517109090...
,2323. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low
affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive
mechanism for D-glucose. J Clin Invest 1994;93:397-404. PMID: 8282810 DOI:
http://dx.doi.org/10.1172/JCI116972
http://dx.doi.org/10.1172/JCI116972...
Glucose
is actively transported from the lumen to the tubular cells essentially by two
transmembrane proteins: one with high capacity-low affinity termed sodium-glucose
transport SGLT-2 and a second with high affinity-low capacity transporter termed
SGLT-1. The SGLT-2 is found in the earlier S1 and S2 segments of the proximal tubule
and the SGLT-1 in the S3 segment of the proximal tubules,1515. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal
Physiol 2001;280:F10-8. PMID: 11133510,1717. Turner RJ, Moran A. Heterogeneity of sodium-dependent D-glucose
transport sites along the proximal tubule: evidence from vesicle studies. Am J
Physiol 1982;242:F406-14. PMID: 6278960 which is
also abundant in the enterocytes of the intestinal mucosa.2121. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose
cotransporters. Physiol Rev 1994;74:993-1026.
Considering that nearly 180 liters of plasma are filtered daily by the kidneys with plasma glucose concentrations ranging between 80-120 mg/dl (an average of 100 mg/dl), the glucose load that crosses the glomeruli is estimated to be around 180 grams per day (Figure 2). Circulating glucose is neither protein-bound nor attached to macromolecules and thus, is freely filtered at the glomerulus. The ultrafiltrate carries the glucose towards the luminal side of the early S1 segment in the proximal tubules, where SGLT-2 is located. The active process of re-uptake of glucose is coupled with the transport of sodium cations and the complex is transferred to the cell membrane at the level of the S1 segment.
Diagram of a proximal tubular cell located in the S1 segment with transport activity and metabolic pathways leading to effective sodium-glucose reabsorption and gluconeogenesis. Glucose coming from the glomerular filtrate enters the urine lumen, couples with sodium ions and binds avidly to the high capacity-low affinity (Km~6.0 mM) SGLT-2 transporter. The energy required to actively transport the sodium-glucose complex into the cell is supplied by ATP generated by the sodium-potassium ATPase pump action, located in the baso-lateral membrane. Proximal tubules utilize primarily fatty acid oxidation to meet their energy demands and are not capable of metabolizing glucose. Thus, glucose reaches the baso-lateral cell membrane intact, where the GLUT-2 transporter promotes a facilitated passive transport, in favor of a glucose concentration gradient. Gluconeogenesis occurs from precursors such as amino acids, lactate and glycerol arising in the urine lumen via active tubular transport. The presence of the enzyme glucose-6-phosphatase enables de-phosphorylation of newly formed glucose-6-phosphate and glucose is also released into the interstitial fluid, via GLUT-2 facilitated transport. The sodium and glucose-rich proximal interstitial fluid exchanges with blood in the peri-tubular capillaries and perfuses the distal nephron.
This same system is also utilized to carry amino acids from the lumen into the proximal tubular cells. The SGLT-2 transport activity across the luminal membrane is driven by an electro-chemical gradient, which is created by the action of the ATPase-mediated sodium-potassium pump located in the baso-lateral membrane of the cells.2121. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994;74:993-1026. The energy consumed in this active transport process is supplied entirely from ATP derived the oxidation of intracellular fatty acids.1111. Wirthensohn G, Guder WG. Renal substrate metabolism. Physiol Rev 1986;66:469-97. PMID: 2938198 As glucose builds up inside the proximal tubular cells, a facilitated passive transport in favor of a concentration gradient and mediated by GLUT-2 transporters, transfers intact glucose molecules out and into the surrounding renal interstitial fluid.2424. Dominguez JH, Camp K, Maianu L, Garvey WT. Glucose transporters of rat proximal tubule: differential expression and subcellular distribution. Am J Physiol 1992;262:F807-12. PMID: 1590425 In addition to restoring glucose (and amino-acids) to the interstitial fluid and eventually to the peripheral circulation, this sodium co-transport process also contributes to the maintenance of fluid and electrolyte balance by the kidney.1515. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-8. PMID: 11133510
In physiologic conditions the high capacity of the SGLT-2 co-transport system is responsible for the reabsorption of nearly 90% of all filtered glucose load. The re-uptake of the remainder 10% of the glucose load is a function of the low-capacity-high affinity SGLT-1 co-transporter and takes place downstream in the S3 segment of the proximal tubules. It is of interest however that despite its minor contribution to glucose re-uptake in the kidney, SGLT-1 represents a major mechanism via which glucose and galactose derived from the meals are absorbed in the intestines.2020. Lee WS, Kanai Y, Wells RG, Hediger MA. The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 1994;269:12032-9. PMID: 8163506,2121. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994;74:993-1026.
On the other hand, the fact that SGLT-2 is exclusively found in the proximal tubules
of the kidney, as opposed to SGLT-1 or GLUT-2, makes this transporter suitable for
more specific renal pharmacologic interventions. Thus, the possibility of interfering
with the activity of the SGLT-2 has become of considerable clinical significance. It
should be emphasized that there is a minor contribution to the glucose load released
into the interstitial fluid provided by the process of renal gluconeogenesis.11. Krebs HA, Hems RA, Gascoyne T. Renal gluconeogenesis. IV.
Gluconeogenesis from substrate combinations. Acta Biol Med Ger
1963;11:607-15.,33. Cersosimo E, Judd RL, Miles JM. Insulin regulation of renal glucose
metabolism in conscious dogs. J Clin Invest 1994;93:2584-9. DOI:
http://dx.doi.org/10.1172/JCI117270
http://dx.doi.org/10.1172/JCI117270...
,66. Eid A, Bodin S, Ferrier B, Delage H, Boghossian M, Martin M, et al.
Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic
fatty rats. J Am Soc Nephrol 2006;17:398-405. DOI:
http://dx.doi.org/10.1681/ASN.2005070742
http://dx.doi.org/10.1681/ASN.2005070742...
This is possible because proximal tubular cells contain the enzymes necessary to
synthesize glucose de novo, including
glucose-6-phosphatase, the last step which enables newly-formed
glucose to be de-phosphorylated and then secreted into the
extra-cellular space.1414. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int
1984;26:101-11. DOI: http://dx.doi.org/10.1038/ki.1984.143
http://dx.doi.org/10.1038/ki.1984.143...
The fact that there is
no detectable biochemical capacity in the proximal tubular cells to either utilize or
store glucose, enables the entire filtered glucose load to be released unaffected
into the renal interstitium. Thus, together with the small fraction of
newly-synthesized glucose added by the proximal tubules the glucose-rich interstitial
fluid exchanges with the renal venous capillaries and reaches the renal vein.
Unlike the proximal nephron, cells in the distal nephron are fully capable of glucose
utilization. In physiologic conditions, the amount of glucose utilized in the distal
segments of the nephron equals that derived from the renal
gluconeogenesis in proximal tubules. This is confirmed by the common
finding that the arterial-renal vein blood glucose concentration difference in the
post-absorptive state is near zero. This is not the case however in more prolonged
fasting conditions and during hypoglycemia, when a net contribution of the kidney to
systemic glucose appearance has been demonstrated.77. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich
J. Uptake and release of glucose by the human kidney. Postabsorptive rates and
responses to epinephrine. J Clin Invest 1995;96:2528-33. DOI:
http://dx.doi.org/10.1172/JCI118314
http://dx.doi.org/10.1172/JCI118314...
8. Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal
glucose metabolism in humans. Am J Physiol 1999;276:E78-84. PMID: 9886953 DOI:
http://dx.doi.org/10.2337/diabetes.48.2.261
http://dx.doi.org/10.2337/diabetes.48.2....
-99. Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S,
Brunengraber H, et al. Contributions by kidney and liver to glucose production in the
postabsorptive state and after 60 h of fasting. Diabetes 1999;48:292-8. DOI:
http://dx.doi.org/10.2337/diabetes.48.2.292
http://dx.doi.org/10.2337/diabetes.48.2....
,2525. Cahill GF Jr, Herrera MG, Morgan AP, Soeldner JS, Steinke J, Levy
PL, et al. Hormone-fuel interrelationships during fasting. J Clin Invest
1966;45:1751-69. PMID: 5926444 DOI:
http://dx.doi.org/10.1172/JCI105481
http://dx.doi.org/10.1172/JCI105481...
,2626. Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF Jr. Liver and
kidney metabolism during prolonged starvation. J Clin Invest 1969;48:574-83. PMID:
5773093 DOI: http://dx.doi.org/10.1172/JCI106016
http://dx.doi.org/10.1172/JCI106016...
The glucose extracted in the distal nephron is directed either towards
glycogen synthesis for storage or to oxidative pathways, depending upon the local
energy demands. Whether this glucose uptake is mediated via an insulin-dependent
mechanism or a facilitated transport still remains controversial.33. Cersosimo E, Judd RL, Miles JM. Insulin regulation of renal glucose
metabolism in conscious dogs. J Clin Invest 1994;93:2584-9. DOI:
http://dx.doi.org/10.1172/JCI117270
http://dx.doi.org/10.1172/JCI117270...
,77. Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich
J. Uptake and release of glucose by the human kidney. Postabsorptive rates and
responses to epinephrine. J Clin Invest 1995;96:2528-33. DOI:
http://dx.doi.org/10.1172/JCI118314
http://dx.doi.org/10.1172/JCI118314...
8. Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal
glucose metabolism in humans. Am J Physiol 1999;276:E78-84. PMID: 9886953 DOI:
http://dx.doi.org/10.2337/diabetes.48.2.261
http://dx.doi.org/10.2337/diabetes.48.2....
-99. Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S,
Brunengraber H, et al. Contributions by kidney and liver to glucose production in the
postabsorptive state and after 60 h of fasting. Diabetes 1999;48:292-8. DOI:
http://dx.doi.org/10.2337/diabetes.48.2.292
http://dx.doi.org/10.2337/diabetes.48.2....
Renal glycogen accumulation is thought to provide for immediate local energy needs,
when blood-borne glucose supply lags behind. The renal oxidation of glucose can be
partial (anaerobic glycolysis) with the release of lactate and ATP,
or complete, a mitochondrial process that yields H2O, CO2 and
ATP. Partial anaerobic glucose oxidation is more prevalent in hypoxic medullary renal
conditions.1212. Weidemann MJ, Krebs HA. The fuel of respiration of rat kidney
cortex. Biochem J 1969;112:149-66. PMID: 5805283
13. Klein KL, Wang MS, Torikai S, Davidson WD, Kurokawa K. Substrate
oxidation by isolated single nephron segments of the rat. Kidney Int 1981;20:29-35.
PMID: 7300110 DOI: http://dx.doi.org/10.1038/ki.1981.100
http://dx.doi.org/10.1038/ki.1981.100...
-1414. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int
1984;26:101-11. DOI: http://dx.doi.org/10.1038/ki.1984.143
http://dx.doi.org/10.1038/ki.1984.143...
Renal glucose utilization occurs exclusively
in distal tubular cells and, in the absence of glucose-6-phospatase
activity no glucose is released back into the interstitial fluid.1414. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int
1984;26:101-11. DOI: http://dx.doi.org/10.1038/ki.1984.143
http://dx.doi.org/10.1038/ki.1984.143...
Moreover, the small amount of glucose utilized
distally does not affect the total glucose load leaving the nephron into the renal
veins.
Glucose handling by the kidney
The fate of the glucose filtered, reabsorbed and excreted in the urine in normal and hyperglycemic conditions depends upon the glomerular filtration rate, the prevalent plasma concentration of glucose and the total transport capacity of the proximal tubules (Figure 3). There is a linear relationship between the filtered glucose load at the glomerulus and plasma glucose and thus, the glucose appearance in the ultrafiltrate will be higher or lower as plasma glucose concentration increases or decreases, respectively.
This graph summarizes the urinary glucose excretion and the renal threshold TmG values (“splay”) calculated in normal healthy individuals (dotted line) and in patients with diabetes prior to and following the administration of SGLT-2 inhibitors (solid lines). The vertical axis expresses urinary glucose excretion rates in grams per day and the horizontal axis represents venous plasma glucose concentrations in mg/dl. Note that in patients with diabetes there is an elevated renal threshold (TmG) that is substantially reduced by the effect of SGLT-2 inhibitors.
To a lesser extent, the same is true for bi-directional changes in the glomerular
filtration rate. The proximal tubular reabsorption rate, on the other hand is only
linear with the glucose load reaching the luminal membrane within a "normal" glycemic
range. Once the maximum tubular reabsorption capacity of the kidney
(Tmax,) is attained the transport process becomes saturated and
glucose spills into the urine. It is worth mentioning that since the
Tmax for glucose varies considerably among the nearly 2 millions
nephrons in both kidneys, the maximum transport capacity is actually a "splay" or a
range of values estimated to be around the calculated Tmax.2121. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose
cotransporters. Physiol Rev 1994;74:993-1026.,2727. Ganong WF. Review of medical physiology. 19th ed. Stamford: Appleton
& Lange; 1999:667-95.,2828. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int
Suppl 2011:S1-6. PMID: 21358696 DOI:
http://dx.doi.org/10.1038/ki.2010.509
http://dx.doi.org/10.1038/ki.2010.509...
The "splay" is derived as the rounding of the curves for maximum glucose reabsorption and excretion rates, which show a non-linear transition as the Tmax value is approached. The Tmax can be determined by artificially elevating plasma glucose levels in a stepwise fashion up to 400-500 mg/dl with simultaneous measurements of the glomerular filtration rate, plasma and urine glucose concentrations, and urine output at given intervals. In individuals with normal kidney function, the calculated maximum tubular glucose transport has been reported between 350-450 mg/min, which corresponds to mean mean venous glucose concentration in the range of 180-200 mg/dl.
Hence, the normal renal threshold (TmG) is often referred to as the
venous plasma glucose concentration ~180 mg/dl.2727. Ganong WF. Review of medical physiology. 19th ed. Stamford: Appleton
& Lange; 1999:667-95. Once this value is exceeded the SGLT system saturation transport
capacity is passed and glycosuria ensues. TmG varies with changes in
glomerular filtration rates such that during pregnancy or with a unilateral kidney,
when glomerular filtration rates increase, glucosuria will occur at plasma glucose
concentrations below 180 mg/dl (lower TmG). Conversely, when
glomerular filtration decreases such as in chronic kidney disease, glucosuria is seen
at plasma glucose levels higher than 220 mg/dl.2727. Ganong WF. Review of medical physiology. 19th ed. Stamford: Appleton
& Lange; 1999:667-95.,2828. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int
Suppl 2011:S1-6. PMID: 21358696 DOI:
http://dx.doi.org/10.1038/ki.2010.509
http://dx.doi.org/10.1038/ki.2010.509...
Of additional
interest, some apparently healthy individuals inherit a genetic abnormality
characterized by a defective SGLT transport system and thus, have constant glycosuria
with normal glomerular filtration rates and in conditions of normoglycemia.2929. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et
al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc
Nephrol 2003;14:2873-82. DOI:
http://dx.doi.org/10.1097/01.ASN.0000092790.89332.D2
http://dx.doi.org/10.1097/01.ASN.0000092...
The observation that the maximum tubular glucose reabsorption rate and the saturation
capacity are markedly affected by chronic hyperglycaemia2222. Mogensen CE. Maximum tubular reabsorption capacity for glucose and
renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic
subjects. Scand J Clin Lab Invest 1971;28:101-9. PMID: 5093515 DOI:
http://dx.doi.org/10.3109/00365517109090668
http://dx.doi.org/10.3109/00365517109090...
,3030. Farber SJ. Berger EY, Earle DP. Effect of diabetes and insulin of
the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest
1951;30:125-9. DOI: http://dx.doi.org/10.1172/JCI102424
http://dx.doi.org/10.1172/JCI102424...
,3131. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose
transporters in human renal proximal tubular cells isolated from the urine of
patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-34. DOI:
http://dx.doi.org/10.2337/diabetes.54.12.3427
http://dx.doi.org/10.2337/diabetes.54.12...
has provided the
basis for a novel approach in the treatment of diabetes. Exposure to hyperglycemia is
reportedly accompanied by an increase in tubular TmG, reflecting
enhanced maximum glucose transport capacity and reabsorption. As a consequence, the
appearance of glucose in the urine tends to occur at plasma glucose concentrations
above the normal renal threshold of 180-200 mg/dl in patients with diabetes.
This adaptation was first reported by Farber et al. in 1951 who
showed that the "splay" for maximal glucose reabsorption (Tmax) was
expanded and the renal threshold augmented in patients with type 2 diabetes by
20-40%.3030. Farber SJ. Berger EY, Earle DP. Effect of diabetes and insulin of
the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest
1951;30:125-9. DOI: http://dx.doi.org/10.1172/JCI102424
http://dx.doi.org/10.1172/JCI102424...
Two decades later, Morgensen2222. Mogensen CE. Maximum tubular reabsorption capacity for glucose and
renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic
subjects. Scand J Clin Lab Invest 1971;28:101-9. PMID: 5093515 DOI:
http://dx.doi.org/10.3109/00365517109090668
http://dx.doi.org/10.3109/00365517109090...
described similar findings in patients with
type 1 diabetes. More recent data derived from in vitro studies
using cultures of proximal renal tubular cells collected from urine samples of
subjects with and without diabetes fully supported these observations. In these
experiments proximal tubular cells from patients with diabetes were shown to have
increased mRNA expression and SGLT-2 protein content. Moreover, using a
radio-labelled glucose analogue functional assay these cells also exhibited an
elevated glucose transport capacity.3131. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose
transporters in human renal proximal tubular cells isolated from the urine of
patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-34. DOI:
http://dx.doi.org/10.2337/diabetes.54.12.3427
http://dx.doi.org/10.2337/diabetes.54.12...
Altogether, these results were interpreted as an indication that there is a
maladaptive response of the kidney to hyperglycemia in diabetes
mellitus. It has been speculated that by increasing glucose reabsorption rates, the
kidney helps to maintain the abnormal status of hyperglycemia, which may in turn lead
to further maladaptation.
Inhibitors of tubular glucose reabsorption
The possibility that the diabetic kidney perpetuates hyperglycemia gave rise to the
notion that agents capable of inhibiting renal glucose reabsorption might be useful
in lowering blood glucose.3232. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA.
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin
in diabetic rats. J Clin Invest 1987;79:1510-5. PMID: 3571496 DOI:
http://dx.doi.org/10.1172/JCI112981
http://dx.doi.org/10.1172/JCI112981...
33. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, et al.
T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel
approach to treating diabetes. Diabetes 1999;48:1794-800. DOI:
http://dx.doi.org/10.2337/diabetes.48.9.1794
http://dx.doi.org/10.2337/diabetes.48.9....
-3434. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review.
Diabetes Metab Res Rev 2005;21:31-8. DOI:
http://dx.doi.org/10.1002/dmrr.532
http://dx.doi.org/10.1002/dmrr.532...
As originally envisioned, SGLT inhibitors
would reduce the tubular capacity for glucose reabsorption and promote glucosuria at
lower plasma glucose levels (low Tm glucose). This hypothesis was
tested with phlorizin, a compound extracted from the root bark of apple tree with
presumed anti-diabetic properties due to its known in vitro
inhibition of tubular glucose transport.
In 1987, Rosettti et al.3232. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA.
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin
in diabetic rats. J Clin Invest 1987;79:1510-5. PMID: 3571496 DOI:
http://dx.doi.org/10.1172/JCI112981
http://dx.doi.org/10.1172/JCI112981...
published data indicating that hyperglycemia, which developed in the fasting and fed
state in rats after partial pancreatectomy, could be reversed with once daily
intra-peritoneal injection of phlorizin. Following the discontinuation of the
injections hyperglycemia was again detected, thus confirming that phlorizin was
responsible for the improvement. These findings suggested that with adequate chemical
blockade of the SGLT transport activity, the renal threshold for glucose reabsorption
could be decreased and better glycemic control achieved in patients with
diabetes.
Although there was some excitement surrounding these findings, the lack of
selectivity of phlorizin, the associated adverse gastro-intestinal effects and the
uncertainty regarding the consequences of the induced glucosuria dampened the initial
enthusiasm for the clinical development of this agent. Furthermore, the realization
that phlorizin was quickly degraded by lactase-phlorizin hydrolase,
was poorly absorbed in the intestines and had very low bioavailability further halted
any investigation using this nonspecific SGLT inhibitor in humans.3434. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review.
Diabetes Metab Res Rev 2005;21:31-8. DOI:
http://dx.doi.org/10.1002/dmrr.532
http://dx.doi.org/10.1002/dmrr.532...
A search for SGLT-2 inhibitors that were more selective and more resistant to
intestinal degradation and had higher plasma bioavailability was launched. Many
agents with SGLT inhibitor properties were obtained by techniques capable of
chemically modifying the parent compound phlorizin ("second generation agents").
Initially in vitro experiments in cultured cell lines expressing
human SGLT-1 and SGLT-2 transporters were conducted to determine the degree of
selectivity of any given SGLT inhibitor using radio-ligand binding assays.3535. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr
Opin Investig Drugs 2007;8:285-92.
36. Tsujihara K, Hongu M, Saito K, Kawanishi H, Kuriyama K, Matsumoto M,
et al. Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4.
Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives
substituted on the B ring. J Med Chem 1999;42:5311-24. DOI:
http://dx.doi.org/10.1021/jm990175n
http://dx.doi.org/10.1021/jm990175n...
-3737. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE,
et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2)
inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes
Obes Metab 2012;14:83-90. DOI:
http://dx.doi.org/10.1111/j.1463-1326.2011.01517.x
http://dx.doi.org/10.1111/j.1463-1326.20...
Following a series of investigations a high degree of selectivity inhibition of
SGLT-2 was initially shown for "empagliflozin"
(L-chloro-4-(β-D-glycopyranos-1-Уl)-2-[4-((S)-tetrahydrofuran-3-Уl-oxy)-benzyl-benzene).
Numerous other compounds were tested in a similar fashion and in
vivo animal studies confirmed that these "second generation" agents were
minimally degraded in the intestines and were only subject to a mild-to-modest total
plasma clearance. Adequate bioavailability in the range of 33 to 80% was documented
for most of these "second-generation" compounds developed.3535. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr
Opin Investig Drugs 2007;8:285-92.
36. Tsujihara K, Hongu M, Saito K, Kawanishi H, Kuriyama K, Matsumoto M,
et al. Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4.
Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives
substituted on the B ring. J Med Chem 1999;42:5311-24. DOI:
http://dx.doi.org/10.1021/jm990175n
http://dx.doi.org/10.1021/jm990175n...
-3737. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE,
et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2)
inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes
Obes Metab 2012;14:83-90. DOI:
http://dx.doi.org/10.1111/j.1463-1326.2011.01517.x
http://dx.doi.org/10.1111/j.1463-1326.20...
The specificity of some of these agents in vivo was questioned by
the recent findings in humans revealing that orally ingested selective SGLT-2
inhibitors must first interact with the SGLT-1 transporters at the brush-border
membrane of enterocytes.3838. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M,
et al. Characterization of renal glucose reabsorption in response to dapagliflozin in
healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-76.
DOI: http://dx.doi.org/10.2337/dc13-0387
http://dx.doi.org/10.2337/dc13-0387...
Because the
enterocytes containing the SGLT-1 transporters are exposed to a greater load of the
SGLT-2 specific inhibitors inside the gut, the binding affinity and thus, the
selectivity is lost. As a result, the activity of the sodium-glucose/galactose
co-transport process as a whole is reduced and there is a transient decline in the
intestinal absorption of these sugars. The selectivity for the renal SGLT-2
transporters is nevertheless regained after partial splanchnic clearance and with
lower circulating plasma drug levels.
Once selective inhibitors reach the kidney via the systemic arterial blood
circulation, they bind avidly to SGLT-2 transporters in the luminal tubular membrane.
In contrast, at much lower concentrations the binding affinity of these agents for
the SGLT-1 transporter located downstream in the same area is severely diminished and
no inhibition of the SGLT-1 activity in the kidney is detected.3535. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr
Opin Investig Drugs 2007;8:285-92. Following an insulin-independent decline in blood glucose,
SGLT-2 inhibition is also accompanied by mild improvement in insulin
sensitivity,3838. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M,
et al. Characterization of renal glucose reabsorption in response to dapagliflozin in
healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-76.
DOI: http://dx.doi.org/10.2337/dc13-0387
http://dx.doi.org/10.2337/dc13-0387...
,3939. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et
al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal
glucose absorption in addition to increasing urinary glucose excretion: results of a
randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61. DOI:
http://dx.doi.org/10.2337/dc12-2391
http://dx.doi.org/10.2337/dc12-2391...
which represents an additional mechanism by
which these agents contribute to glycemic control in patients with type 2 diabetes.
Moreover, recent findings reported in a SGLT-2 knockout mouse model provide evidence
for an alternative approach to improving glycemic control and reducing insulin
sensitivity with preservation of beta-cell function, by simply reducing the renal
threshold and promoting renal glycosuria.4040. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW,
Pongratz RL, et al. SGLT2 deletion improves glucose homeostasis and preserves
pancreatic beta-cell function. Diabetes 2011;60:890-8. DOI:
http://dx.doi.org/10.2337/db10-1328
http://dx.doi.org/10.2337/db10-1328...
Clinical pharmacology and pharmacokinetics
The maximum inhibitory effect achievable on the renal glucose re-uptake with the use
of selective blockade of the tubular SGTL-2 transporter activity in humans has been
reported at 30-50%.4141. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li
L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria
in healthy subjects. Clin Pharmacol Ther 2009;85:520-6. DOI:
http://dx.doi.org/10.1038/clpt.2008.251
http://dx.doi.org/10.1038/clpt.2008.251...
,4242. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only
30-50% of renal glucose reabsorption in humans? Diabetes
2012;6:2199-204. It has been postulated that the efficacy of
these agents is somewhat limited, in part because of the competitive nature of the
inhibitory binding process. There is also the possibility that very low levels of the
active drug reach the tubular luminal membrane, the main site of the drug action.
Finally, and perhaps most importantly, the extent to which a compensatory enhancement
in the glucose reabsorption capacity of the SGLT-1 co-transporter or by a yet
unidentified tubular glucose transport system, located downstream contributes to the
low effectiveness of these agents has not been defined.1515. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal
Physiol 2001;280:F10-8. PMID: 11133510,1919. Sacktor B. Sodium-coupled hexose transport. Kidney Int
1989;36:342-50. PMID: 2687560 DOI:
http://dx.doi.org/10.1038/ki.1989.202
http://dx.doi.org/10.1038/ki.1989.202...
Once
plasma steady-state concentrations of the SGLT inhibitor are reached (4 to 5 days),
the total amount of glucose excreted in the urine is around 50-80 grams per day. This
results from the partial blockade of the SGLT-2 co-transporter and reflects a shift
to the left in the maximum tubular transport capacity with a substantial decrease in
the renal threshold [TmG].3838. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M,
et al. Characterization of renal glucose reabsorption in response to dapagliflozin in
healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-76.
DOI: http://dx.doi.org/10.2337/dc13-0387
http://dx.doi.org/10.2337/dc13-0387...
,4141. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li
L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria
in healthy subjects. Clin Pharmacol Ther 2009;85:520-6. DOI:
http://dx.doi.org/10.1038/clpt.2008.251
http://dx.doi.org/10.1038/clpt.2008.251...
Clinical observational studies conducted in healthy non-diabetic and in diabetic
subjects have indicated that the appearance of glucosuria can be detected within 8-16
weeks after the oral intake of the first dose of an SGLT-2 inhibitor.4343. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of
dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control
with metformin: a randomised, double-blind, placebo-controlled trial. Lancet
2010;375:2223-33. PMID: 20609968 DOI:
http://dx.doi.org/10.1016/S0140-6736(10)60407-2
http://dx.doi.org/10.1016/S0140-6736(10)...
,4444. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze
M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2
diabetes who have inadequate glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
DOI: http://dx.doi.org/10.2337/dc11-0606
http://dx.doi.org/10.2337/dc11-0606...
Actually, it has been estimated that following a short therapy period
with SGLT-2 inhibitors glucosuria can be detected both in subjects with and without
diabetes at plasma glucose values ranging anywhere from 40-120 mg/dl.3838. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M,
et al. Characterization of renal glucose reabsorption in response to dapagliflozin in
healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-76.
DOI: http://dx.doi.org/10.2337/dc13-0387
http://dx.doi.org/10.2337/dc13-0387...
This remarkable shift in the renal threshold
for glucose reabsorption contributes to a significant decrease in circulating plasma
glucose, which is accomplished with a daily loss of 200-320 calories.
These changes combined can provide much desired benefits for obese patients with
diabetes. The decline in plasma glucose concentration following the use of SGLT
inhibitors has been recently reported to be attenuated by a rise in plasma glucagon
accompanied by an elevation in endogenous glucose production.3939. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et
al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal
glucose absorption in addition to increasing urinary glucose excretion: results of a
randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61. DOI:
http://dx.doi.org/10.2337/dc12-2391
http://dx.doi.org/10.2337/dc12-2391...
,4545. Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2
inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 2012;12:230-8.
DOI: http://dx.doi.org/10.1007/s11892-012-0275-6
http://dx.doi.org/10.1007/s11892-012-027...
These
findings were documented in subjects who had received SGLT-2 inhibitors for a short
period of time and who had experienced a drop in plasma glucose levels, but with no
evidence of hypoglycemia. These intriguing observations have raised new questions
regarding potential interactions of the kidney and liver in glucose regulation and
counter-regulation, and will require confirmation.
Following oral administration SGLT-2 inhibitors are rapidly absorbed with peak plasma
concentrations (median T
max
) occurring 1-2 hours post-dose. Plasma C
max
and the area under the curve (AUC) increase in a
dose-proportional manner with apparent terminal half-life (t
1/2
) of varying from 10 up to 13 hours. The active drug reaches a steady-state
usually within 4 to 5 days.3737. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE,
et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2)
inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes
Obes Metab 2012;14:83-90. DOI:
http://dx.doi.org/10.1111/j.1463-1326.2011.01517.x
http://dx.doi.org/10.1111/j.1463-1326.20...
,3838. DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M,
et al. Characterization of renal glucose reabsorption in response to dapagliflozin in
healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-76.
DOI: http://dx.doi.org/10.2337/dc13-0387
http://dx.doi.org/10.2337/dc13-0387...
,4141. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li
L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria
in healthy subjects. Clin Pharmacol Ther 2009;85:520-6. DOI:
http://dx.doi.org/10.1038/clpt.2008.251
http://dx.doi.org/10.1038/clpt.2008.251...
The major metabolic elimination of SGLT-2 inhibitors is via hepatic
glucuronidation and the inactive metabolites are released into peripheral
circulation. There is minimal CYP3A4-mediated oxidative metabolic degradation. Thus,
clinically relevant effects of other drugs on the pharmacokinetics of SGLT-2
inhibitors via cytochrome P450 are unlikely to occur. Also, since the CYP450 enzyme
system is not induced and is only minimally attenuated by SGLT-2 inhibitors only
negligible changes in drugs utilizing the same hepatic metabolic processes have been
reported.
In contrast, a decrease in total exposure to active SGLT-2 inhibitors occurs when UGT
(glucuronosyl transferase) inducers, such as rifampin, phenytoin and phenobarbital
are co-administered. Plasma digoxin levels tend to increase and require closer
monitoring when used in combination with SGLT-2 inhibitors. When using oral
radio-labeled SGLT-2 inhibitors in normal healthy volunteers nearly 50% of the active
drug is recovered in feces together with minor amounts (less than 10%) of some
inactive metabolites; less than 1% of the oral dose is excreted intact in the
urine.4646. Tahrani AA, Barnett AH, Bailey CJ. SGLT2 inhibitors in the
management of diabetes. Lancet Diabetes Endocrinol 2013;1:140-51 DOI:
http://dx.doi.org/10.1016/S2213-8587(13)70050-0
http://dx.doi.org/10.1016/S2213-8587(13)...
Safety and efficacy of SGLT inhibitors
The fact that selective inhibitors of SGLT-2 lower plasma glucose concentration via
an insulin-independent manner, and thus with minimal risk of hypoglycemia, combined
with the potential to induce simultaneous body weight loss has generated considerable
clinical interest.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
48. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A
study of dapagliflozin in patients with type 2 diabetes receiving high doses of
insulin plus insulin sensitizers: applicability of a novel insulin-independent
treatment. Diabetes Care 2009;32:1656-62. DOI:
http://dx.doi.org/10.2337/dc09-0517
http://dx.doi.org/10.2337/dc09-0517...
49. Kipnes MS. Sodium-glucose co-transporter 2 inhibitor in the
treatment of type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011;
1:145-56. DOI: http://dx.doi.org/10.4155/cli.10.12
http://dx.doi.org/10.4155/cli.10.12...
50. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et
al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a
sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with
type 2 diabetes. Diabetes Care 2012;35:1232-8. DOI:
http://dx.doi.org/10.2337/dc11-1926
http://dx.doi.org/10.2337/dc11-1926...
-5151. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze
M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2
diabetes who have inadequate glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
DOI: http://dx.doi.org/10.2337/dc11-0606
http://dx.doi.org/10.2337/dc11-0606...
Several SGLT-2 inhibitors are currently in
development and some have already been approved for use in the treatment of patients
with type 2 diabetes. Results from a few selected clinical trials are summarized on
Table 1.
Reported clinical efficacy of various SGLT -2 inhibitors used in pivotal clinical trials in the treatment of type 2 diabetes
Most studies have shown consistent and unequivocal improvements in glycemic control
in a variety of diabetic patients with a decline in both fasting and postprandial
plasma glucose. The mean reported decrease in the glycosylated hemoglobin
(HbA1c) values was approximately 1.0%, which was initially documented
over a period of 6 months. More recent preliminary data have confirmed that these
changes can be sustained with safety up to 4 years.5252. Blonde L, Wilding JP, Chiasson J-L, Polidori D, Meininger G, Stein
P. Prolonged use of dapagliflozin versus glipizide in obese type 2 diabetic patients.
Abstract 1110-P. Presented at the 73rd Annual Meeting of the American Diabetes
Association, 14-18 June 2013; Chicago, IL. The degree of glycemic control attained with SGLT-2 inhibitors was
shown to be either comparable or superior to anti-diabetic agents routinely
recommended in standard practice.4949. Kipnes MS. Sodium-glucose co-transporter 2 inhibitor in the
treatment of type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011;
1:145-56. DOI: http://dx.doi.org/10.4155/cli.10.12
http://dx.doi.org/10.4155/cli.10.12...
50. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et
al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a
sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with
type 2 diabetes. Diabetes Care 2012;35:1232-8. DOI:
http://dx.doi.org/10.2337/dc11-1926
http://dx.doi.org/10.2337/dc11-1926...
-5151. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze
M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2
diabetes who have inadequate glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
DOI: http://dx.doi.org/10.2337/dc11-0606
http://dx.doi.org/10.2337/dc11-0606...
The exact placement of SGLT-2 inhibitors in algorithms designed to guide management
of diabetes remains undetermined and is likely to be somewhat controversial.5353. American Diabetes Association. Standards of medical care in
diabetes--2013. Diabetes Care 2013;36:S11-66. DOI:
http://dx.doi.org/10.2337/dc13-S011
http://dx.doi.org/10.2337/dc13-S011...
54. Schwartz SS. A practice-based approach to the 2012 position
statement of the American Diabetes Association and the European Association for the
Study of Diabetes. Curr Med Res Opin 2013;29:793-9. DOI:
http://dx.doi.org/10.1185/03007995.2013.798637
http://dx.doi.org/10.1185/03007995.2013....
-5555. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT,
Bray GA, et al.; AACE Task Force for Developing Diabetes Comprehensive Care Plan.
American Association of Clinical Endocrinologists Medical Guidelines for Clinical
Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract
2011;17:1-53. DOI: http://dx.doi.org/10.4158/EP.17.S2.1
http://dx.doi.org/10.4158/EP.17.S2.1...
These drugs are known to be effective as monotherapy and, even though
the decrease in blood glucose can be attained within a wide range of plasma glucose
concentration, whether early in the disease (or in pre-diabetes) the tubular
reabsorption capacity is abnormally enhanced has not been fully determined. Moreover,
with limited clinical experience and considering the added cost this class of drugs
is more likely to be used later, rather than earlier in the treatment of type 2
diabetes. The possibility nevertheless of combining these agents with other
well-established anti-diabetic drugs, oral and injectables seems more reasonable.
Taking into account the unique mechanism of action of SGLT-2 inhibitors, maybe they
are best if indicated in patients with poorly-controlled type 2 diabetes in whom oral
treatment has been exhausted and the initiation of injectable agents or insulin
replacement therapy is eminent.
These suggested therapeutic options are not based on firm scientific evidence and represent but one viewpoint. The ultimate decision as to when and how to best use SGLT-inhibitors during the course of diabetes treatment will require additional data as well as the experience acquired over a prolonged period of time.
Body weight loss was anticipated and has occurred in almost all diabetic patients who
received therapy with SGLT-2 inhibitors in pivotal clinical trials.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
48. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A
study of dapagliflozin in patients with type 2 diabetes receiving high doses of
insulin plus insulin sensitizers: applicability of a novel insulin-independent
treatment. Diabetes Care 2009;32:1656-62. DOI:
http://dx.doi.org/10.2337/dc09-0517
http://dx.doi.org/10.2337/dc09-0517...
49. Kipnes MS. Sodium-glucose co-transporter 2 inhibitor in the
treatment of type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011;
1:145-56. DOI: http://dx.doi.org/10.4155/cli.10.12
http://dx.doi.org/10.4155/cli.10.12...
50. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et
al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a
sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with
type 2 diabetes. Diabetes Care 2012;35:1232-8. DOI:
http://dx.doi.org/10.2337/dc11-1926
http://dx.doi.org/10.2337/dc11-1926...
51. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze
M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2
diabetes who have inadequate glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
DOI: http://dx.doi.org/10.2337/dc11-0606
http://dx.doi.org/10.2337/dc11-0606...
-5252. Blonde L, Wilding JP, Chiasson J-L, Polidori D, Meininger G, Stein
P. Prolonged use of dapagliflozin versus glipizide in obese type 2 diabetic patients.
Abstract 1110-P. Presented at the 73rd Annual Meeting of the American Diabetes
Association, 14-18 June 2013; Chicago, IL. The usual amount of body weight lost was reported in the range of 2 to
4 kilograms over a period of observation of 6 months, with only a few outliers.
Interestingly, studies using other drugs that promote body weight usually provide
results with noticeable individual variability, whereas SGLT-2 inhibitors tend to
induce nearly equal body weight loss in just about everyone treated. A recent study
indicated that the majority of the weight reduction was due to the loss of body fat
mass, ~50% each in the abdominal and subcutaneous fat depots, with minimal changes in
lean body mass.5656. Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J,
Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and
regional adipose tissue distribution in patients with type 2 diabetes mellitus with
inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31.
PMID: 22238392 DOI: http://dx.doi.org/10.1210/jc.2011-2260
http://dx.doi.org/10.1210/jc.2011-2260...
The stabilization of the body weight achieved 6 months after the initiation of therapy, which has been confirmed to persist up to 4 years with the continued use of SGLT-2 inhibitors is regarded as a remarkable accomplishment and provides further reassurance to those who manage obese type 2 diabetic patients.5252. Blonde L, Wilding JP, Chiasson J-L, Polidori D, Meininger G, Stein P. Prolonged use of dapagliflozin versus glipizide in obese type 2 diabetic patients. Abstract 1110-P. Presented at the 73rd Annual Meeting of the American Diabetes Association, 14-18 June 2013; Chicago, IL. Whether a later compensatory increase in appetite and/or a change in energy expenditure will occur in response to the loss of calories in the urine over longer periods of time should not be entirely discarded. As a reminder, these agents are not approved for the sole treatment of overweight and obese individuals who do not have a diagnosis of type 2 diabetes.
The low incidence of hypoglycemia is a clinically relevant and important characteristic associated with the use of SGLT-2 inhibitors in the management of type 2 diabetes. This results from the fact that the mechanisms underlying the glucose-lowering effect of a partial blockade of the tubular glucose re-uptake are insulin-independent and do not involve direct changes in insulin secretion.
Furthermore, the rate of urinary glucose excretion is proportionate to the
circulating plasma glucose concentration (i.e., glucose-dependent glucose excretion)
and thus, it becomes almost negligible in conditions of very low plasma glucose
concentrations. In contrast, when SGLT-2 inhibitors are used in combination with
insulin secretagogues (sulfonylurea, meglitinides) or together with insulin
injections the risk for hypoglycemia is magnified.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
48. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A
study of dapagliflozin in patients with type 2 diabetes receiving high doses of
insulin plus insulin sensitizers: applicability of a novel insulin-independent
treatment. Diabetes Care 2009;32:1656-62. DOI:
http://dx.doi.org/10.2337/dc09-0517
http://dx.doi.org/10.2337/dc09-0517...
49. Kipnes MS. Sodium-glucose co-transporter 2 inhibitor in the
treatment of type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011;
1:145-56. DOI: http://dx.doi.org/10.4155/cli.10.12
http://dx.doi.org/10.4155/cli.10.12...
50. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et
al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a
sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with
type 2 diabetes. Diabetes Care 2012;35:1232-8. DOI:
http://dx.doi.org/10.2337/dc11-1926
http://dx.doi.org/10.2337/dc11-1926...
51. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze
M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2
diabetes who have inadequate glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
DOI: http://dx.doi.org/10.2337/dc11-0606
http://dx.doi.org/10.2337/dc11-0606...
-5252. Blonde L, Wilding JP, Chiasson J-L, Polidori D, Meininger G, Stein
P. Prolonged use of dapagliflozin versus glipizide in obese type 2 diabetic patients.
Abstract 1110-P. Presented at the 73rd Annual Meeting of the American Diabetes
Association, 14-18 June 2013; Chicago, IL. There is no
current approved indication for the co-administration of SGLT-2 inhibitors with
insulin therapy in type 1 diabetes, just as there are no data on the safety and
efficacy of these agents in pediatric patients under 18 years of age.
Some important and a few unexpected findings have been reported in patients with type
2 diabetes who were exposed to various SGLT-2 inhibitors in clinical trials (Table 2). Following initial treatment a
transient period (days to weeks) of polyuria, urinary frequency with increased
thirst, often characterized as a simple state of dehydration was described in 3-5% of
all study subjects.5050. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et
al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a
sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with
type 2 diabetes. Diabetes Care 2012;35:1232-8. DOI:
http://dx.doi.org/10.2337/dc11-1926
http://dx.doi.org/10.2337/dc11-1926...
,5151. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze
M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2
diabetes who have inadequate glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
DOI: http://dx.doi.org/10.2337/dc11-0606
http://dx.doi.org/10.2337/dc11-0606...
Two-thirds of these individuals had symptoms
of postural dizziness and most of them had documented orthostatic hypotension. The
majority recovered uneventfully, presumably because blood volume and fluid balance
were appropriately corrected by alternate renal and some other mechanisms. Of note,
dehydration and orthostatism was more common in elderly diabetic patients who were
taking anti-hypertensive drugs and/or diuretics.
commonly reported adve rse eve nts of various SGLT -2 inhibitors used in pivotal clinical trials in the treatment of type 2 diabetes
Despite the transient nature of these acute hemodynamic events, greater caution and a
special attention to this vulnerable population will be required by prescribing
physicians and health care providers. For reasons that are not entirely clear, a
slight and consistent decrease in systolic and diastolic blood pressure has been
recorded in nearly all diabetic patients treated with SGLT-2 inhibitors for at least
6 months.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
48. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A
study of dapagliflozin in patients with type 2 diabetes receiving high doses of
insulin plus insulin sensitizers: applicability of a novel insulin-independent
treatment. Diabetes Care 2009;32:1656-62. DOI:
http://dx.doi.org/10.2337/dc09-0517
http://dx.doi.org/10.2337/dc09-0517...
49. Kipnes MS. Sodium-glucose co-transporter 2 inhibitor in the
treatment of type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011;
1:145-56. DOI: http://dx.doi.org/10.4155/cli.10.12
http://dx.doi.org/10.4155/cli.10.12...
50. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et
al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a
sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with
type 2 diabetes. Diabetes Care 2012;35:1232-8. DOI:
http://dx.doi.org/10.2337/dc11-1926
http://dx.doi.org/10.2337/dc11-1926...
51. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze
M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2
diabetes who have inadequate glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
DOI: http://dx.doi.org/10.2337/dc11-0606
http://dx.doi.org/10.2337/dc11-0606...
-5252. Blonde L, Wilding JP, Chiasson J-L, Polidori D, Meininger G, Stein
P. Prolonged use of dapagliflozin versus glipizide in obese type 2 diabetic patients.
Abstract 1110-P. Presented at the 73rd Annual Meeting of the American Diabetes
Association, 14-18 June 2013; Chicago, IL.
Whether this potential beneficial effect can be related to changes in blood volume and hydration status and/or to a direct or indirect vascular dilation property of SGLT-2 inhibitors remains undetermined.
Rare cases of mild hyperkalemia following the administration of SGLT-2 inhibitors
have been reported, primarily in patients with some degree of renal
insufficiency.5757. Woo V, Davis M, De Zeeuw D, Bakris G, Perkovic V, Gassmann-Mayer C,
et al. Change in HbA1c with canagliflozin in subjects with T2DM and Stage 3 Chronic
Kidney Disease. Abstract 73-LB. Presented at the 73rd Annual Meeting of the American
Diabetes Association, 14-18 June 2013; Chicago, IL. Nearly all diabetic
patients who experienced serum potassium elevations were using potassium-sparing
diuretics, angiotensin-converting enzyme inhibitors or angiotensin receptor blocking
agents. We speculate that by further altering the tubular-glomerular feedback loop
with the reduction of the sodium-glucose reabsorption in proximal tubules these
agents may exacerbate an underlying hyporeninemic-hypoaldosteronism state, commonly
seen in type 2 diabetes.5858. Knochel JP. The syndrome of hyporeninemic hypoaldosteronism. Annu
Rev Med 1979;30:145-53. DOI:
http://dx.doi.org/10.1146/annurev.me.30.020179.001045
http://dx.doi.org/10.1146/annurev.me.30....
No serious clinical
consequences however have yet been registered in association with hyperkalemia
induced by SGLT-2 inhibitors.
Considering the recommendations for the use of SGLT-2 inhibitors are limited to lower doses and should be given only to diabetic patients with estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73 m2, the occurrence of hyperkalemia is expected to be a rare event. Because of pure inefficacy, these agents are not indicated in patients with advanced end-stage renal disease and those on renal dialysis. In case of inadvertent drug overdose and intoxication, SGLT-2 inhibitors cannot be removed from the circulation efficiently by hemodialysis. Almost nothing is known about untoward effects associated with acute elevations and tissue accumulation of the native SGLT-2 inhibitor compounds and their metabolites.
In patients with mild-to-moderate hepatic insufficiency, nonetheless there is no need
for adjustments in dose, although the safety and efficacy of these SGLT-2 inhibitors
have never been tested in patients with severe hepatic insufficiency. Also, the use
of SGLT-2 inhibitors is contra-indicated during pregnancy and in lactating diabetic
women, since newborn animals exposed to this agent exhibit a multitude of kidney and
urogenital malformations.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
According to results from one large pivotal study presented earlier to the Food and
Drug Administration (FDA) Advisory Committee, 9 cases of bladder cancer out of 5,501
patients (0.16%) were reported in association with the use of dapagliflozin, as
opposed to only one patient out of 3,184 (0.03%) treated with
placebo/comparator.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
During careful
analyses of the data it was noted that all bladder cancers occurred in male patients
and that 7 of all 10 patients with the diagnosis had had hematuria prior to the
initiation of the study treatment. Furthermore, eight patients with bladder cancer
were current or former smokers, five of them were diagnosed at < 6 months from the
start of dapagliflozin therapy, and none diagnosed with treatment longer than 24
months. In the same clinical trials, breast cancer developed in ten out of 2,531
women (0.40%) treated with dapagliflozin vs. three out of 1,359
women (0.22%) in the placebo/comparator groups. All breast cancers were recorded in
female patients above the age of 50 years and, in fact 10 of 13 cases occurred in
women above the age of 60 years.
The diagnosis was confirmed in women exposed to dapagliflozin for less than one year
and in two cases the presence of breast cancer was documented within the first eight
weeks of treatment. Based on these observations, the FDA concluded that there were
too few events to establish causality, a decision supported by the fact that no
carcinogenicity or mutagenic signal has been described during pre-clinical animal
studies. Although the accumulation of large amounts of glucose in the bladder urine
over time cannot be entirely rule out as a putative carcinogenic factor, it is
reassuring to know that SGLT-2 transporter proteins are not expressed either in human
bladder or in breast tissue.5959. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al.
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related
family members. Diabetes Ther 2010;1:57-92. DOI:
http://dx.doi.org/10.1007/s13300-010-0006-4
http://dx.doi.org/10.1007/s13300-010-000...
There was a noticeable increase in the incidence of urinary tract and genital
infections in patients with type 2 diabetes who were treated with SGLT-2 inhibitors
reported in all clinical trials.4848. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A
study of dapagliflozin in patients with type 2 diabetes receiving high doses of
insulin plus insulin sensitizers: applicability of a novel insulin-independent
treatment. Diabetes Care 2009;32:1656-62. DOI:
http://dx.doi.org/10.2337/dc09-0517
http://dx.doi.org/10.2337/dc09-0517...
49. Kipnes MS. Sodium-glucose co-transporter 2 inhibitor in the
treatment of type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011;
1:145-56. DOI: http://dx.doi.org/10.4155/cli.10.12
http://dx.doi.org/10.4155/cli.10.12...
50. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et
al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a
sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with
type 2 diabetes. Diabetes Care 2012;35:1232-8. DOI:
http://dx.doi.org/10.2337/dc11-1926
http://dx.doi.org/10.2337/dc11-1926...
51. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze
M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2
diabetes who have inadequate glycemic control with metformin: a randomized, 52-week,
double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
DOI: http://dx.doi.org/10.2337/dc11-0606
http://dx.doi.org/10.2337/dc11-0606...
-5252. Blonde L, Wilding JP, Chiasson J-L, Polidori D, Meininger G, Stein
P. Prolonged use of dapagliflozin versus glipizide in obese type 2 diabetic patients.
Abstract 1110-P. Presented at the 73rd Annual Meeting of the American Diabetes
Association, 14-18 June 2013; Chicago, IL. Nearly all
infections were limited to the lower urinary tract and were reported in ~8-13% of
participants receiving SGLT-2 inhibitors, but only in ~3-8% of those randomized to
either placebo or a comparator drug. Similarly, genital infections developed in
~12-15% of patients taking SGLT-2 inhibitors, whereas those using placebo or a
comparator drug had an incidence no higher than ~5%.
These observations were derived from studies that included more than 10,000 patients
with type 2 diabetes followed by at least 2 years of exposure to various SGLT-2
inhibitors.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
Women, especially those with
a positive past medical history were more commonly affected, although the vast
majority of infections resolved with standard treatment, did not require hospital
admissions, and recurrences were infrequent. Actually, many of the participants who
developed urinary and genital infections elected to continue with the treatment,
particularly those in whom glucose control and body weight loss were apparent. Less
than 2% of all patients treated with SGLT-2 inhibitors who developed genital mycosis,
namely balano-postitis, were uncircumcised men.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
Inasmuch as the potential for long-term adverse effects of SGLT-2 inhibitors on
kidney function is unpredictable, we can take some comfort on the observations that
individuals with "familial renal glucosuria" are essentially disease-free and live
near-normal lives.6060. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a
mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5:133-41. DOI:
http://dx.doi.org/10.2215/CJN.04010609
http://dx.doi.org/10.2215/CJN.04010609...
This is an autossomal recessive disorder with either complete deficiency or decreased affinity for the SGLT-2 co-transporter protein. The genetics of "familial renal glucosuria" have been studied extensively and 21 different mutations in the gene for SGLT2 were detected. Homozygous individuals tend to have glycosuria that varies from 15 up to 200 g/day, whereas pure heterozygous family members have either mild glycosuria or none at all. Because this condition is characterized by persistent urinary glucose excretion, even within the normal range of plasma glucose concentration these individuals have difficulty maintaining body weight.
There is no evidence of renal glomerular or tubular dysfunction, as assessed by
kidney function and renal histological evaluations. Hypoglycemia is uncommon and the
incidence of diabetes mellitus, chronic renal insufficiency and urinary tract
infections is comparable to the general population. The diagnosis of "familial renal
glucosuria" must be distinguished however from other complex tubular disorders that
can be associated with some morbidity.6060. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a
mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5:133-41. DOI:
http://dx.doi.org/10.2215/CJN.04010609
http://dx.doi.org/10.2215/CJN.04010609...
There is no clinical evidence that the use of SGLT-2 inhibitors in patients with type
2 diabetes is associated with improved cardiovascular outcomes. A long-term trial is
underway to address this question and we shall soon have an answer. In the meantime,
the available data indicate that these drugs are cardiovascular safe and so far have
not been accompanied by increases in cardiovascular events.4747. Food and Drug Administration Advisory Committee (19th July 2011
& 21st March 2013) [accessed online on several occasions]. Available from:
http://www.fda.gov
http://www.fda.gov...
The observation that there is a slight but consistent decrease in systolic and diastolic blood pressure sustained for up to 104 weeks contrasts with the slight elevation in plasma low-density lipoprotein (LDL) cholesterol particles described in most clinical studies, which makes it even more difficult to predict the final results of the ongoing cardiovascular outcomes trial.
In summary, the kidney plays an important role in glucose homeostasis, contributes to glucose regulation and counter-regulation, and in sparing glucose also helps to preserve the energy balance. These remarkable functions are achieved by an active proximal tubular mega-transport system that promotes complete glucose reabsorption and by the minimal intrinsic glucose production that often matches renal glucose utilization. Chronic hyperglycemia is associated with an increase in renal threshold and renal glucosuria occurs at higher than normal plasma glucose concentrations.
As a consequence, specific inhibition of the high capacity renal sodium-glucose co-transporter (SGLT-2) has emerged as a potential pharmacological intervention, which by decreasing tubular glucose reabsorption rates induces glucosuria and reduces blood glucose levels. In addition, continuous loss of calories in the urine is accompanied by a sustained decrease in body weight/fat in obese patients with type 2 diabetes. Initial observations in pre-clinical studies and in clinical trials have raised expectations for the utilization of SGLT-2 inhibitors in the treatment of type 2 diabetes. The data collected so far demonstrating a clinically significant glucose-lowering effect, body weight loss and negligible risk of hypoglycemia in patients treated with this novel class of drugs are very consistent.
The development of transient polyuria with dehydration and the occasional hypotension, particularly in elderly diabetic patients is of concern. The high frequency of urinary tract infections and genital mycosis requires close monitoring. Lower doses of SGLT-2 can be used safely in individuals with mild-to-moderate, but not in those with severe and end-stage renal insufficiency. Whether there is any long-term damage to the kidney is unknown and cardiovascular benefits are yet to be demonstrated with the use of these novel agents. Also, adverse effects on bone and mineral metabolism have not been sufficiently investigated. Some SGLT-2 inhibitors are now approved for the treatment of type 2 diabetes, either as monotherapy or in combination with other anti-diabetic medications. As long as patients can tolerate these agents, given all that we know today, SGLT-2 inhibitors if used with caution and in the proper patient may provide an additional safe and efficacious therapeutic option in the management of type 2 diabetes.
References
-
1Krebs HA, Hems RA, Gascoyne T. Renal gluconeogenesis. IV. Gluconeogenesis from substrate combinations. Acta Biol Med Ger 1963;11:607-15.
-
2Cahill GF Jr. Starvation in man. N Engl J Med 1970;282:668-75. DOI: http://dx.doi.org/10.1056/NEJM197003192821209
» http://dx.doi.org/10.1056/NEJM197003192821209 -
3Cersosimo E, Judd RL, Miles JM. Insulin regulation of renal glucose metabolism in conscious dogs. J Clin Invest 1994;93:2584-9. DOI: http://dx.doi.org/10.1172/JCI117270
» http://dx.doi.org/10.1172/JCI117270 -
4Cersosimo E, Ajmal M, Naukam RJ, Molina PE, Abumrad NN. Role of the kidney in plasma glucose regulation during hyperglycemia. Am J Physiol 1997;272:E756-61. PMID: 9176172
-
5Cersosimo E, Molina PE, Abumrad NN. Renal lactate metabolism and gluconeogenesis during insulin-induced hypoglycemia. Diabetes 1998;47:1101-6. DOI: http://dx.doi.org/10.2337/diabetes.47.7.1101
» http://dx.doi.org/10.2337/diabetes.47.7.1101 -
6Eid A, Bodin S, Ferrier B, Delage H, Boghossian M, Martin M, et al. Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats. J Am Soc Nephrol 2006;17:398-405. DOI: http://dx.doi.org/10.1681/ASN.2005070742
» http://dx.doi.org/10.1681/ASN.2005070742 -
7Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest 1995;96:2528-33. DOI: http://dx.doi.org/10.1172/JCI118314
» http://dx.doi.org/10.1172/JCI118314 -
8Cersosimo E, Garlick P, Ferretti J. Insulin regulation of renal glucose metabolism in humans. Am J Physiol 1999;276:E78-84. PMID: 9886953 DOI: http://dx.doi.org/10.2337/diabetes.48.2.261
» http://dx.doi.org/10.2337/diabetes.48.2.261 -
9Ekberg K, Landau BR, Wajngot A, Chandramouli V, Efendic S, Brunengraber H, et al. Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. Diabetes 1999;48:292-8. DOI: http://dx.doi.org/10.2337/diabetes.48.2.292
» http://dx.doi.org/10.2337/diabetes.48.2.292 -
10Cersosimo E, Garlick P, Ferretti J. Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes. Diabetes 2001;50:2087-93. DOI: http://dx.doi.org/10.2337/diabetes.50.9.2087
» http://dx.doi.org/10.2337/diabetes.50.9.2087 -
11Wirthensohn G, Guder WG. Renal substrate metabolism. Physiol Rev 1986;66:469-97. PMID: 2938198
-
12Weidemann MJ, Krebs HA. The fuel of respiration of rat kidney cortex. Biochem J 1969;112:149-66. PMID: 5805283
-
13Klein KL, Wang MS, Torikai S, Davidson WD, Kurokawa K. Substrate oxidation by isolated single nephron segments of the rat. Kidney Int 1981;20:29-35. PMID: 7300110 DOI: http://dx.doi.org/10.1038/ki.1981.100
» http://dx.doi.org/10.1038/ki.1981.100 -
14Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int 1984;26:101-11. DOI: http://dx.doi.org/10.1038/ki.1984.143
» http://dx.doi.org/10.1038/ki.1984.143 -
15Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-8. PMID: 11133510
-
16Aronson PS, Sacktor B. The Na+ gradient-dependent transport of D-glucose in renal brush border membranes. J Biol Chem 1975;250:6032-9. PMID: 1150669
-
17Turner RJ, Moran A. Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol 1982;242:F406-14. PMID: 6278960
-
18Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 1987;330:379-81. PMID: 2446136 DOI: http://dx.doi.org/10.1038/330379a0
» http://dx.doi.org/10.1038/330379a0 -
19Sacktor B. Sodium-coupled hexose transport. Kidney Int 1989;36:342-50. PMID: 2687560 DOI: http://dx.doi.org/10.1038/ki.1989.202
» http://dx.doi.org/10.1038/ki.1989.202 -
20Lee WS, Kanai Y, Wells RG, Hediger MA. The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 1994;269:12032-9. PMID: 8163506
-
21Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994;74:993-1026.
-
22Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28:101-9. PMID: 5093515 DOI: http://dx.doi.org/10.3109/00365517109090668
» http://dx.doi.org/10.3109/00365517109090668 -
23Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93:397-404. PMID: 8282810 DOI: http://dx.doi.org/10.1172/JCI116972
» http://dx.doi.org/10.1172/JCI116972 -
24Dominguez JH, Camp K, Maianu L, Garvey WT. Glucose transporters of rat proximal tubule: differential expression and subcellular distribution. Am J Physiol 1992;262:F807-12. PMID: 1590425
-
25Cahill GF Jr, Herrera MG, Morgan AP, Soeldner JS, Steinke J, Levy PL, et al. Hormone-fuel interrelationships during fasting. J Clin Invest 1966;45:1751-69. PMID: 5926444 DOI: http://dx.doi.org/10.1172/JCI105481
» http://dx.doi.org/10.1172/JCI105481 -
26Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF Jr. Liver and kidney metabolism during prolonged starvation. J Clin Invest 1969;48:574-83. PMID: 5773093 DOI: http://dx.doi.org/10.1172/JCI106016
» http://dx.doi.org/10.1172/JCI106016 -
27Ganong WF. Review of medical physiology. 19th ed. Stamford: Appleton & Lange; 1999:667-95.
-
28Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl 2011:S1-6. PMID: 21358696 DOI: http://dx.doi.org/10.1038/ki.2010.509
» http://dx.doi.org/10.1038/ki.2010.509 -
29Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82. DOI: http://dx.doi.org/10.1097/01.ASN.0000092790.89332.D2
» http://dx.doi.org/10.1097/01.ASN.0000092790.89332.D2 -
30Farber SJ. Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30:125-9. DOI: http://dx.doi.org/10.1172/JCI102424
» http://dx.doi.org/10.1172/JCI102424 -
31Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-34. DOI: http://dx.doi.org/10.2337/diabetes.54.12.3427
» http://dx.doi.org/10.2337/diabetes.54.12.3427 -
32Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-5. PMID: 3571496 DOI: http://dx.doi.org/10.1172/JCI112981
» http://dx.doi.org/10.1172/JCI112981 -
33Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-800. DOI: http://dx.doi.org/10.2337/diabetes.48.9.1794
» http://dx.doi.org/10.2337/diabetes.48.9.1794 -
34Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8. DOI: http://dx.doi.org/10.1002/dmrr.532
» http://dx.doi.org/10.1002/dmrr.532 -
35Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007;8:285-92.
-
36Tsujihara K, Hongu M, Saito K, Kawanishi H, Kuriyama K, Matsumoto M, et al. Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem 1999;42:5311-24. DOI: http://dx.doi.org/10.1021/jm990175n
» http://dx.doi.org/10.1021/jm990175n -
37Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14:83-90. DOI: http://dx.doi.org/10.1111/j.1463-1326.2011.01517.x
» http://dx.doi.org/10.1111/j.1463-1326.2011.01517.x -
38DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-76. DOI: http://dx.doi.org/10.2337/dc13-0387
» http://dx.doi.org/10.2337/dc13-0387 -
39Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61. DOI: http://dx.doi.org/10.2337/dc12-2391
» http://dx.doi.org/10.2337/dc12-2391 -
40Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011;60:890-8. DOI: http://dx.doi.org/10.2337/db10-1328
» http://dx.doi.org/10.2337/db10-1328 -
41Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6. DOI: http://dx.doi.org/10.1038/clpt.2008.251
» http://dx.doi.org/10.1038/clpt.2008.251 -
42Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;6:2199-204.
-
43Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33. PMID: 20609968 DOI: http://dx.doi.org/10.1016/S0140-6736(10)60407-2
» http://dx.doi.org/10.1016/S0140-6736(10)60407-2 -
44Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22. DOI: http://dx.doi.org/10.2337/dc11-0606
» http://dx.doi.org/10.2337/dc11-0606 -
45Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 2012;12:230-8. DOI: http://dx.doi.org/10.1007/s11892-012-0275-6
» http://dx.doi.org/10.1007/s11892-012-0275-6 -
46Tahrani AA, Barnett AH, Bailey CJ. SGLT2 inhibitors in the management of diabetes. Lancet Diabetes Endocrinol 2013;1:140-51 DOI: http://dx.doi.org/10.1016/S2213-8587(13)70050-0
» http://dx.doi.org/10.1016/S2213-8587(13)70050-0 -
47Food and Drug Administration Advisory Committee (19th July 2011 & 21st March 2013) [accessed online on several occasions]. Available from: http://www.fda.gov
» http://www.fda.gov -
48Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62. DOI: http://dx.doi.org/10.2337/dc09-0517
» http://dx.doi.org/10.2337/dc09-0517 -
49Kipnes MS. Sodium-glucose co-transporter 2 inhibitor in the treatment of type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011; 1:145-56. DOI: http://dx.doi.org/10.4155/cli.10.12
» http://dx.doi.org/10.4155/cli.10.12 -
50Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al.; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8. DOI: http://dx.doi.org/10.2337/dc11-1926
» http://dx.doi.org/10.2337/dc11-1926 -
51Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22. DOI: http://dx.doi.org/10.2337/dc11-0606
» http://dx.doi.org/10.2337/dc11-0606 -
52Blonde L, Wilding JP, Chiasson J-L, Polidori D, Meininger G, Stein P. Prolonged use of dapagliflozin versus glipizide in obese type 2 diabetic patients. Abstract 1110-P. Presented at the 73rd Annual Meeting of the American Diabetes Association, 14-18 June 2013; Chicago, IL.
-
53American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013;36:S11-66. DOI: http://dx.doi.org/10.2337/dc13-S011
» http://dx.doi.org/10.2337/dc13-S011 -
54Schwartz SS. A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Curr Med Res Opin 2013;29:793-9. DOI: http://dx.doi.org/10.1185/03007995.2013.798637
» http://dx.doi.org/10.1185/03007995.2013.798637 -
55Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al.; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17:1-53. DOI: http://dx.doi.org/10.4158/EP.17.S2.1
» http://dx.doi.org/10.4158/EP.17.S2.1 -
56Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31. PMID: 22238392 DOI: http://dx.doi.org/10.1210/jc.2011-2260
» http://dx.doi.org/10.1210/jc.2011-2260 -
57Woo V, Davis M, De Zeeuw D, Bakris G, Perkovic V, Gassmann-Mayer C, et al. Change in HbA1c with canagliflozin in subjects with T2DM and Stage 3 Chronic Kidney Disease. Abstract 73-LB. Presented at the 73rd Annual Meeting of the American Diabetes Association, 14-18 June 2013; Chicago, IL.
-
58Knochel JP. The syndrome of hyporeninemic hypoaldosteronism. Annu Rev Med 1979;30:145-53. DOI: http://dx.doi.org/10.1146/annurev.me.30.020179.001045
» http://dx.doi.org/10.1146/annurev.me.30.020179.001045 -
59Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010;1:57-92. DOI: http://dx.doi.org/10.1007/s13300-010-0006-4
» http://dx.doi.org/10.1007/s13300-010-0006-4 -
60Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5:133-41. DOI: http://dx.doi.org/10.2215/CJN.04010609
» http://dx.doi.org/10.2215/CJN.04010609
Publication Dates
-
Publication in this collection
Jan-Mar 2014
History
-
Received
30 Nov 2013 -
Accepted
06 Jan 2014